A Tampa-area startup has quietly raised $2.7 million for software that promises to automate the messy clinical workflows of functional medicine practices, according to a Form D filing submitted to the SEC on September 22. Bioinsights, which operates from Lutz, Florida, is building what it describes as an "all-in-one clinical operating system" that uses predictive modeling to connect patient symptoms with treatment protocols—a pitch aimed at a niche but growing slice of alternative healthcare.
Seven investors participated in the offering, which launched with an initial sale on September 13, the filing shows. The company declined to identify backers or discuss valuation when contacted.
Delaware-incorporated and founded in 2026, Bioinsights markets to practitioners who treat patients through diet, supplements, and lifestyle modifications rather than conventional pharmaceuticals. Its core product is a proprietary algorithm the company calls the Predictive Dysfunction Index, which calculates probabilities for various physiological imbalances by analyzing patient biomarkers against a library of more than 300 treatment protocols.
What It Actually Does
The platform bundles patient intake forms, lab ordering across what the company says are 100-plus test panels covering 500 biomarkers, electronic prescribing, telehealth, and supplement fulfillment through an integrated pharmacy. Bioinsights claims the software saves providers north of 790 hours annually, though no independent audit backs that number. Marketing materials describe a "logistic/Bayesian probability model" that recalculates dysfunction likelihoods as new patient data arrives.
The system also generates clinical progress notes and patient letters in what the company pegs at 90 seconds, plus real-time transcription during telehealth visits. Whether practitioners find that automation useful or intrusive remains to be seen.
The Team Behind It
CEO Travis Bond, an MD with an MBA, has a track record in health technology. He previously founded CareSync, a Tampa-based chronic care management company, and led Altoida, a digital neurodiagnostics firm, according to the company website and industry coverage published between 2016 and 2023. Co-founder Erin Coletti is a physician the company describes as having logged more than 40,000 patient encounters. Dennis Mihale is listed as chief medical officer, with Maximilian Bügler overseeing technology.
Bond posted on LinkedIn late last month that Bioinsights is "taking AI to a whole new level: partnering with the provider at the point of care." The framing suggests ambitions beyond simple workflow automation.
A Crowded Corner of Healthcare IT
Functional medicine practitioners already have options. Specialized EHRs such as Practice Better, Cerbo (formerly MD HQ), OptiMantra, and Power2Practice have staked out territory in the integrative health space, according to software comparison sites and practitioner forums reviewed in September. Practice Better and Cerbo both offer protocol libraries and lab integrations tailored to these workflows.
Bioinsights references an "$82 billion market" in its materials, a figure that appears to draw from a 2025 academic whitepaper citing the Global Wellness Institute's U.S. "Traditional & Complementary Medicine" segment—a broad umbrella encompassing therapies well beyond functional medicine. More conservative estimates from commercial research firms place the U.S. complementary and alternative medicine market between $41 billion and $45 billion in 2024.
Scaling Up
The company is hiring a director of clinical product with a base salary starting at $135,000 for a hybrid role in Lutz, according to a job posting on Indeed accessed late September. The listing emphasizes ownership of AI-driven clinical decision support features. LinkedIn lists the company at 2–10 employees.
The SEC filing indicates a planned raise of $7.9 million total, leaving $5.1 million still to close. Bioinsights has not publicly announced the round or attached a formal series label to the fundraise. Whether it completes the full amount may hinge on proving the software can convert a skeptical practitioner base accustomed to juggling multiple disconnected tools rather than betting on a single platform.
